Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSCPA.L Regulatory News (SCPA)

  • There is currently no data for SCPA

Trading Statement

12 Apr 2018 07:00

RNS Number : 6330K
Scapa Group PLC
12 April 2018
 

 

12 April 2018

 

Scapa Group plc ("Scapa" or "the Group")

 

Year-end trading update

 

Scapa Group plc (AIM: SCPA) is today providing an unaudited year end update for the twelve months ended 31 March 2018.  

 

The Group performed well and the good progress reported in the Interim Results has continued. Overall Group results are in line with the improved expectations outlined in the Group's October trading update.

Healthcare: Revenues grew 3.8% for the year, despite currency headwinds in H2. Sales growth in H2 was strong at 6.8% on a constant currency basis. Margins for the year are expected to be above 15% reflecting the investment in the integration of two technology transfers completed during the year.

Industrial: Industrial continues to deliver on its asset optimisation strategy. Industrial margin further improved driven by the benefit of Asian restructuring and more efficient cost to serve. The Markel acquisition is complete and site consolidations are underway.

Healthy cash flow in the period ensured the Group ended the year with net debt of ÂŁ3.8m, after the acquisition of Markel Industries for US$10.2m (ÂŁ7.6m) and BioMed Laboratories LLC for US$19m (ÂŁ13.6m).

Heejae Chae, CEO commented:

"This year we have delivered another set of strong results, and completed two acquisitions: Markel, our first Industrial acquisition, and BioMed, our first Healthcare acquisition outside adhesive technology. We also completed two technology transfers in Healthcare as we execute our growth strategy. I believe there is clear potential, in both Healthcare and Industrial, to further improve performance through organic growth, efficiency and acquisitions.

It is with great sadness that we announced yesterday a fatal accident at the Dunstable facility in the UK. I join with all of my colleagues and fellow directors in expressing our sincere condolences to the family and friends of the deceased."

Scapa expects to report its full year results on 22 May 2018.

This announcement contains inside information.

For further information:

Scapa Group plc Heejae Chae - Chief Executive Tel: 0161 301 7430

Graham Hardcastle - Finance Director

 

Numis Securities Limited Mark Lander, Richard Thomas Tel: 020 7260 1000

(Nominated Adviser/Joint Broker)

 

Berenberg Chris Bowman Tel: 020 3207 7800

(Joint Broker)

 

Weber Shandwick Financial PR Nick Oborne Tel: 0207 067 0000

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFKDDPPBKDBQD
Date   Source Headline
1st Mar 201710:22 amRNSAdditional Listing
23rd Feb 201711:03 amRNSHolding(s) in Company
16th Feb 20179:21 amRNSHolding(s) in Company
7th Feb 20174:16 pmRNSBlock listing Interim Review
3rd Feb 20173:53 pmRNSHolding(s) in Company
26th Jan 201710:10 amRNSDirector/PDMR Shareholding
25th Jan 20174:33 pmRNSBlock listing Interim Review
25th Jan 201711:49 amRNSHolding(s) in Company
23rd Jan 20179:18 amRNSDirector/PDMR Shareholding
9th Jan 20179:41 amRNSAdditional Listing
22nd Dec 20162:15 pmRNSAdditional Listing
15th Dec 20167:00 amRNSDirectorate Change
13th Dec 20161:29 pmRNSAdditional Listing
24th Nov 20164:30 pmRNSDirector/PDMR Shareholding
24th Nov 20164:20 pmRNSDirector/PDMR Shareholding
22nd Nov 20164:20 pmRNSAdditional Listing
22nd Nov 20167:00 amRNSHalf-year Report
12th Oct 20167:00 amRNSTrading Statement
27th Sep 20162:53 pmRNSDirector/PDMR Shareholding
21st Sep 20161:51 pmRNSAdditional Listing
6th Sep 201610:24 amRNSAdditional Listing
2nd Sep 201611:20 amRNSBlock listing Interim Review
31st Aug 20169:14 amRNSTotal Voting Rights
26th Aug 20167:00 amRNSDirector/PDMR Shareholding
12th Aug 201611:24 amRNSBlock listing Interim Review
11th Aug 20161:30 pmRNSDirector/PDMR Shareholding
10th Aug 201610:08 amRNSDirector/PDMR Shareholding
19th Jul 20164:58 pmRNSAdditional Listing
19th Jul 20167:00 amRNSAGM Statement
11th Jul 20163:48 pmRNSDirector/PDMR Shareholding
5th Jul 20162:25 pmRNSHolding(s) in Company
1st Jul 20162:58 pmRNSDirector/PDMR Shareholding
1st Jun 20163:49 pmRNSAdditional Listing
1st Jun 20167:00 amRNSAppointment of Joint Broker
24th May 20167:00 amRNSAcquisition
24th May 20167:00 amRNSFinal Results
18th May 201610:01 amRNSAdditional Listing
11th May 201610:45 amRNSHolding(s) in Company
18th Apr 20167:00 amRNSDirectorate Change
14th Apr 20167:00 amRNSTrading Statement
2nd Mar 20169:06 amRNSBlocklisting Interim Review
8th Feb 20169:49 amRNSBlocklisting Interim Review
28th Jan 20167:00 amRNSDirectorate Change
31st Dec 20157:00 amRNSTotal Voting Rights
15th Dec 20159:57 amRNSHolding(s) in Company
14th Dec 20158:26 amRNSHolding(s) in Company
14th Dec 20158:21 amRNSDirector/PDMR Shareholding
8th Dec 201511:46 amRNSHolding(s) in Company
8th Dec 201511:42 amRNSHolding(s) in Company
1st Dec 201510:52 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.